Your browser doesn't support javascript.
loading
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.
Talbot, Thomas; D'Alessio, Antonio; Pinter, Matthias; Balcar, Lorenz; Scheiner, Bernhard; Marron, Thomas U; Jun, Tomi; Dharmapuri, Sirish; Ang, Celina; Saeed, Anwaar; Hildebrand, Hannah; Muzaffar, Mahvish; Fulgenzi, Claudia A M; Amara, Suneetha; Naqash, Abdul Rafeh; Gampa, Anuhya; Pillai, Anjana; Wang, Yinghong; Khan, Uqba; Lee, Pei-Chang; Huang, Yi-Hsiang; Bengsch, Bertram; Bettinger, Dominik; Mohamed, Yehia I; Kaseb, Ahmed; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza; Nishida, Naoshi; Kudo, Masatoshi; Weinmann, Arndt; Galle, Peter R; Muhammed, Ambreen; Cortellini, Alessio; Vogel, Arndt; Pinato, David J.
Afiliación
  • Talbot T; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • D'Alessio A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Pinter M; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Balcar L; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Scheiner B; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Marron TU; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Jun T; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Dharmapuri S; Sema4, Stamford, Connecticut, USA.
  • Ang C; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Saeed A; Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
  • Hildebrand H; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, Kansas, USA.
  • Muzaffar M; Division of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, Kansas, USA.
  • Fulgenzi CAM; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Amara S; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Naqash AR; Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
  • Gampa A; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Pillai A; Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
  • Wang Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
  • Khan U; Section of Gastroenterology, Hepatology & Nutrition, the University of Chicago Medicine, Chicago, Illinois, USA.
  • Lee PC; Section of Gastroenterology, Hepatology & Nutrition, the University of Chicago Medicine, Chicago, Illinois, USA.
  • Huang YH; Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bengsch B; Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA.
  • Bettinger D; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Mohamed YI; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Kaseb A; Institute of Clinical Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan.
  • Pressiani T; Department of Medicine II, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Personeni N; Department of Medicine II, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Rimassa L; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Nishida N; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kudo M; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Weinmann A; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Galle PR; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Muhammed A; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Cortellini A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Vogel A; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Pinato DJ; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Liver Int ; 43(3): 695-707, 2023 03.
Article en En | MEDLINE | ID: mdl-36577703
ABSTRACT
BACKGROUND AND

AIMS:

Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including the continuation of ICI, treatment switching to tyrosine kinase inhibitors (TKIs) and cessation of anticancer therapy. We sought to characterise the relationship between radiological patterns of progression and survival post-ICI, also appraising treatment strategies.

METHODS:

We screened 604 HCC patients treated with ICIs, including only those who experienced PD by data cut-off. We evaluated post-progression survival (PPS) according to the treatment strategy at PD and verified its relationship with radiological patterns of progression intrahepatic growth (IHG), new intrahepatic lesion (NIH), extrahepatic growth (EHG), new extrahepatic lesion (NEH) and new vascular invasion (nVI).

RESULTS:

Of 604 patients, 364 (60.3%) experienced PD during observation. Median PPS was 5.3 months (95% CI 4.4-6.9; 271 events). At the data cut-off, 165 patients (45%) received no post-progression anticancer therapy; 64 patients (17.6%) continued ICI beyond PD. IHG (HR 1.64 [95% CI 1.21-2.22]; p = .0013) and nVI (HR 2.15 [95% CI 1.38-3.35]; p = .0007) were associated with shorter PPS. Multivariate models adjusted for progression patterns, treatment line and albumin-bilirubin grade and Eastern Cooperative Oncology Group performance status at PD confirmed receipt of ICI beyond PD with (HR 0.17, 95% CI 0.09-0.32; p < .0001) or without subsequent TKI (HR 0.39, 95% CI 0.26-0.58; p < .0001) as predictors of prolonged PPS versus no anticancer therapy.

CONCLUSIONS:

ICI-TKI sequencing is a consolidated option in advanced HCC. nVI and IHG predict a poorer prognosis. Despite lack of recommendation, the continuation of ICI beyond progression in HCC is adopted clinically future efforts should appraise which patients benefit from this approach.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Guideline / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Guideline / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido